Is there a U.S. drug lag? The timing of new pharmaceutical approvals in the G-7 countries and Switzerland

Medical Care Research and Review

Volumn 53, Issue 2, 1996, Pages 162-178

  Schweitzer, Stuart O ^a   Schweitzer, Maurice E ^b   Sourty Le Guellec, Marie Jo ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c Centre de Recherche

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMPARATIVE STUDY; DRUG APPROVAL; EUROPE; FOOD AND DRUG ADMINISTRATION; JAPAN; ORGANIZATION AND MANAGEMENT; STATISTICAL MODEL; STATISTICS; SWITZERLAND; TIME MANAGEMENT; UNITED STATES;

DRUG APPROVAL; EUROPE; JAPAN; MODELS, STATISTICAL; OWNERSHIP; SWITZERLAND; TIME MANAGEMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0030162618     PISSN: 10775587     EISSN: None     Source Type: Journal    
DOI: 10.1177/107755879605300203     Document Type: Article

References (29)

1. Andersson, F. "The Drug Lag Issue: The Debate Seen from an International Perspective." International Journal of Health Services 22 (1992): 53-72.
2. Barral, P. E. "Fifteen Years of Pharmaceutical Research Results throughout the World (1975-1989)." Unpublished report, Fondation Rhône-Poulenc Santé, 1990.
3. Berlin, H., and B. Jonsson. "International Dissemination of New Drugs: A Comparative Study of Six Countries." Managerial and Decision Economics 7 (1986): 235-42.
4. Burstall, M. L. "Europe after 1992: Implications for Pharmaceuticals." Health Affairs 10 (fall 1991): 157-71.
5. Coppinger, P. L., C. C. Peck, and R. J. Temple. "Understanding Comparisons of Drug Introductions between the United States and the United Kingdom." Clinical Pharmacological Therapeutics 46 (1989): 139-45.
6. DeHaen, P. "The Drug Lag - Does It Exist in Europe?" Drug Intelligence and Clinical Pharmacy 9 (1975): 144-50.
7. Drug Facts and Comparisons. St. Louis, MO: Facts and Comparisons, 1992.
8. Drug Price Competition and Patent Term Restoration Act of 1984. Public Law 98-417. 98th Cong., 2d sess., 24 September 1984.
9. Fielding, J. E., and P. J. Lancry. "Lessons from France - 'Vive la Difference': The French Health Care System and U.S. Health System Reform." Journal of the American Medical Association 270: (1993): 748-56.
10. Grabowski, H. G. "Regulation and the International Diffusion of Pharmaceuticals." In The International Supply of Medicines: Implications of U.S. Regulatory Reform, edited by R. B. Helms, 5-36. Washington, DC: American Enterprise Institute for Public Policy Research, 1980.
11. Grabowski, H. G., S. O. Schweitzer, and R. S. Shiota. "The Medicaid Drug Lag: Adoption of New Drugs by State Medicaid Formularies." Pharmacoeconomics 1 (1992 Suppl.): 32-40.
12. Grabowski, H. G., J. M. Vernon, and L. G. Thomas. "Estimating the Effects of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical Industry." Journal of Law and Economics 2 (1978): 133-63.
13. Hass, A. E., Jr. Compendium of New Drug Approvals in Eleven Industrialized Countries, 1970-1983. NTIS Publication No. PB85-189926. Rockville, MD: Food and Drug Administration, 1985.
14. Kaitin, K. "Reply to 'Understanding Comparisons of Drug Introductions between the United States and the United Kingdom'" Clinical Pharmacological Therapeutics 46 (1989): 146-8.
15. Peltzman, S. "An Evaluation of Consumer Protection Legislation: The 1962 Drug Amendments." Journal of Political Economy 8 (1973): 1049-91.
16. Prescription Drug User Fee Act of 1992. Public Law 102-571. 102nd Cong., 2d sess., 29 October 1992.
17. Rodwin, V. G., and S. Sandier. "Health Care under French National Health Insurance." Health Affairs 12 (fall 1993): 111-31.
18. Schweitzer, S. O. "An International Comparison of the Approval of New Pharmaceuticals." In Managing Technology in Health Care Organizations, edited by O. Heller and E. Geisler. Boston: Kluwer Academic Publishers, 1996.
19. Schweitzer, S. O., H. Salehi, and N. Boling. "The Social Drug Lag." Social Science and Medicine 21 (1985): 1077-82.
20. Silverman, M., and P. R. Lee. Pills, Profits, and Politics, Berkeley: University of California Press, 1974.
21. Simmons, H. E. "The Drug Regulatory System of the United States Food and Drug Administration: A Defense of Current Requirements for Safety and Efficacy." International Journal of Health Services 4 (1974): 95-107.
22. Thomas, L. G. "Regulation and Firm Size: FDA Impacts on Innovation." RAND Journal of Economics 21 (winter 1990): 497-517.
23. U.S. Congress. General Accounting Office (GAO). FDA Drug Approval: Review Time Has Decreased in Recent Years. Letter Report No. GAO/PEMD-96-1. Washington, DC: Government Printing Office, 1995.
24. U.S. Congress. Office of Technology Assessment. Pharmaceutical R&D: Costs, Risks, and Rewards. Report No. OTA-H-522. Washington, DC: U.S. Government Printing Office, 1993.
25. U.S. Department of Health and Human Services. 1988. Health United States 1988. Washington, DC: U.S. Government Printing Office.
26. _. 1989. Health United States 1989. Washington, DC: U.S. Government Printing Office.
27. Wardell, W. M. "Introduction of New Therapeutic Drugs in the United States and Great Britain: An International Comparison. Clinical Pharmacological Therapeutics 14 (1973): 773-90.
28. _. "The Drug Lag Revisited: Comparison by Therapeutic Area of Patterns of Drugs Marketed in the United States and Great Britain from 1972 through 1976." Clinical Pharmacological Therapeutics 24 (1978): 499-524.
29. Wiggins, S. N. "Product Availability Regulation and New Drug Introductions: Some New Evidence from the 1970s." Review of Economics and Statistics 63 (1981): 615-9.